TR199900267T2 - GnRH-Lökotoksin kimeralari. - Google Patents
GnRH-Lökotoksin kimeralari.Info
- Publication number
- TR199900267T2 TR199900267T2 TR1999/00267T TR9900267T TR199900267T2 TR 199900267 T2 TR199900267 T2 TR 199900267T2 TR 1999/00267 T TR1999/00267 T TR 1999/00267T TR 9900267 T TR9900267 T TR 9900267T TR 199900267 T2 TR199900267 T2 TR 199900267T2
- Authority
- TR
- Turkey
- Prior art keywords
- gnrh
- systems
- sequences
- kotoksin
- kimeralar
- Prior art date
Links
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 6
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 4
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 abstract 1
- 101710170970 Leukotoxin Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6833—Viral toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Yeni imünolojik sistemleri, bu sistemleri kodlayan DNA ve bu sistemlerin kullanimlari anlatilmistir. Tasiyici sistemler, en azindan bir tekrarlanan GnRH dekapeptid dizisini ya da bir seçilmis GnRH molekülünün en azindan bir epitopuna karsi gelen bir dizinin en azindan bir tekrarlanan birimini içeren bir ya da daha çok seçilmis GnRH multimerine kaynasmis bir lökotoksin polipeptidini kapsayan kimerik proteinleri kapsamaktadir. Bulusa göre, seçilmis GnRH dizilerinin hepsi ayni olabilir, ya da bunlar, GnRH dizileri bir bagisiklik karsiligini ortaya çikarabildigi sürece, GnRH'nin farkli türevleri, analoglari, varyantlari ya da epitoplarina karsi gelebilmektedir. Lökotoksin, kendisine kaynasmis GnRH multimerlerinin imünogenikligini arttirma yönünde islev görmektedir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/694,865 US5837268A (en) | 1991-10-16 | 1996-08-09 | GnRH-leukotoxin chimeras |
Publications (1)
Publication Number | Publication Date |
---|---|
TR199900267T2 true TR199900267T2 (tr) | 2000-09-21 |
Family
ID=24790566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR1999/00267T TR199900267T2 (tr) | 1996-08-09 | 1997-08-08 | GnRH-Lökotoksin kimeralari. |
Country Status (20)
Country | Link |
---|---|
US (3) | US5837268A (tr) |
EP (1) | EP0920510B1 (tr) |
JP (1) | JP2001502887A (tr) |
KR (1) | KR20000029911A (tr) |
CN (1) | CN1328381C (tr) |
AT (1) | ATE300616T1 (tr) |
AU (1) | AU725233B2 (tr) |
BR (1) | BR9711123A (tr) |
CA (1) | CA2262524A1 (tr) |
DE (1) | DE69733823T2 (tr) |
DK (1) | DK0920510T3 (tr) |
ES (1) | ES2247637T3 (tr) |
HU (1) | HUP0001538A3 (tr) |
IL (1) | IL128123A0 (tr) |
NO (1) | NO990533L (tr) |
NZ (1) | NZ333999A (tr) |
PL (1) | PL331537A1 (tr) |
PT (1) | PT920510E (tr) |
TR (1) | TR199900267T2 (tr) |
WO (1) | WO1998006848A1 (tr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837268A (en) | 1991-10-16 | 1998-11-17 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
US6797272B1 (en) | 1991-10-16 | 2004-09-28 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
AUPM885194A0 (en) * | 1994-10-14 | 1994-11-10 | Council Of The Queensland Institute Of Medical Research, The | Synthetic peptides and vaccines comprising same |
IL116436A (en) | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
IL118570A (en) * | 1996-06-04 | 2007-06-17 | Shai Yarkoni | Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma |
AUPO776897A0 (en) | 1997-07-09 | 1997-07-31 | Csl Limited | A method of achieving production gains in livestock and agents useful for same |
US20080233086A1 (en) * | 1997-09-05 | 2008-09-25 | Canbiocin Inc. | Expression Vectors for Treating Bacterial Infections |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
BR9910905A (pt) * | 1998-06-04 | 2001-02-13 | Metamorphix Inc | Vacinas de gnrh para suprimir comportamento reprodutivo em animais. |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
EP2172214A3 (en) * | 1999-03-12 | 2011-03-16 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
WO2001085763A2 (en) | 2000-05-05 | 2001-11-15 | Aphton Corporation | Chimeric peptide immunogens their preparation and use |
WO2002043770A2 (en) * | 2000-12-01 | 2002-06-06 | Conforma Therapeutic Corporation | Homing peptide multimers, their preparation and uses |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US7220421B2 (en) * | 2001-06-19 | 2007-05-22 | The Regents Of The University Of California | Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of Moraxella bovis infections |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
AU2003262379A1 (en) * | 2002-04-16 | 2003-11-03 | Auburn University | TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH |
US7794734B2 (en) * | 2002-10-30 | 2010-09-14 | The Board Of Regents For Oklahoma State University | Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2004105791A2 (en) * | 2003-06-02 | 2004-12-09 | The Talwar Research Foundation | Recombinant anti-lhrh vaccines |
KR100711143B1 (ko) | 2003-10-16 | 2007-04-24 | (주)넥스젠 | 면역 거세용 재조합 폴리펩타이드 및 이를 포함하는 백신 |
WO2005120552A1 (en) * | 2004-06-11 | 2005-12-22 | Ym Biosciences Inc. | METHODS AND FORMULATIONS OF GnRH/LEUKOTOXIN CHIMERAS FOR TESTOSTERONE SUPPRESSION |
EP1771483A1 (en) | 2004-07-20 | 2007-04-11 | Symphogen A/S | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
WO2006007853A2 (en) * | 2004-07-20 | 2006-01-26 | Symphogen A/S | A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
CA2695399C (en) | 2007-08-02 | 2017-10-17 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2239267B1 (en) * | 2008-01-31 | 2016-10-12 | Osaka University | Tag peptide and use thereof |
US9056918B2 (en) | 2008-04-25 | 2015-06-16 | University Of Saskatchewan | Prion epitopes and methods of use thereof |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
AU2010234193B2 (en) | 2009-04-06 | 2015-08-20 | University Of Saskatchewan | Methods and compositions for treating and preventing Shiga toxin-producing Escherichia coli infection |
WO2012114323A1 (en) | 2011-02-22 | 2012-08-30 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
ES2781579T3 (es) * | 2013-03-18 | 2020-09-03 | Statens Seruminstitut | Vacunas contra Chlamydia sp |
US9814769B2 (en) * | 2014-09-30 | 2017-11-14 | Qatar University | Vaccines against pathogenic Escherichia coli and methods of using the same |
US20180042998A1 (en) | 2015-03-10 | 2018-02-15 | University Of Massachusetts | Targeting gdf6 and bmp signaling for anti-melanoma therapy |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4692412A (en) * | 1972-10-06 | 1987-09-08 | Livingston Virginia W | Method of preparing an autogenous vaccine |
US4608251A (en) * | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
US4556555A (en) * | 1985-01-25 | 1985-12-03 | North Carolina State University | Process for the immunological neutering of animals |
WO1986007383A1 (en) * | 1985-06-04 | 1986-12-18 | Biotechnology Research Partners, Ltd. | Autoantigen vaccines |
US5374426A (en) * | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
US5028423A (en) * | 1986-10-07 | 1991-07-02 | Immunex Corporation | Immunogenic conjugates comprising leukotoxin peptide fragments |
US5055400A (en) * | 1986-11-26 | 1991-10-08 | University Of Guelph | Leukotoxin gene of pasteurella haemolytica |
US4975420A (en) * | 1987-09-30 | 1990-12-04 | University Of Saskatchewan | Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals |
NL8900726A (nl) * | 1989-03-23 | 1990-10-16 | Stichting Centr Diergeneeskund | Peptide, immunogene samenstelling en vaccin- of geneesmiddelpreparaat; werkwijze voor het immuniseren van een zoogdier tegen lhrh, en werkwijze voor het verbeteren van de vleeskwaliteit van varkens. |
CA2014033C (en) * | 1989-04-07 | 1993-02-09 | Stephen D. Acres | Compositions and treatments for pneumonia in animals |
CA2040441C (en) * | 1989-08-25 | 1998-03-31 | Gregory J. Russell-Jones | Fusion proteins |
ES2108693T3 (es) * | 1990-04-05 | 1998-01-01 | Univ Saskatchewan | Compuestos y tratamientos para la neumonia en animales. |
US5594107A (en) * | 1990-08-22 | 1997-01-14 | University Of Saskatchewan | Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon |
US5238823A (en) * | 1990-08-22 | 1993-08-24 | Veterinary Infectious Disease Organization | Interleukin-2-leukotoxin gene fusions and uses thereof |
US5273889A (en) * | 1990-08-22 | 1993-12-28 | University Of Saskatchewan | Gamma-iterferon-leukotoxin gene fusions and uses thereof |
GB9100825D0 (en) * | 1991-01-15 | 1991-02-27 | Univ Guelph | Pasteurella haemolytica glycoprotease gene and the purified enzyme |
GB9101550D0 (en) * | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
AU634379B2 (en) * | 1991-04-29 | 1993-02-18 | Csl Limited | Recombinant immunocastration vaccine |
WO1993002890A1 (de) * | 1991-08-09 | 1993-02-18 | Elpro Ag Berlin-Industrieelektronik Und Anlagenbau- | Schaltungsanordnung für ein gleichrichter-unterwerk |
US5723129A (en) * | 1991-10-16 | 1998-03-03 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
US5422110A (en) * | 1991-10-16 | 1995-06-06 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
WO1993008290A1 (en) * | 1991-10-16 | 1993-04-29 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
US5837268A (en) * | 1991-10-16 | 1998-11-17 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
CA2081950A1 (en) * | 1991-11-01 | 1993-05-02 | Reggie Y. C. Lo | Vaccine for the prevention of infections caused by pasteurella haemolytica |
CA2133441C (en) * | 1992-04-09 | 2007-03-27 | Andrew A. Potter | Haemophilus somnus immunogenic proteins |
US5534256A (en) * | 1992-07-02 | 1996-07-09 | University Of Saskatchewan | Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins |
US5547657A (en) * | 1994-10-11 | 1996-08-20 | Eastman Chemical Company | Low-irritation anesthetic and antiseptic mouth rinse |
-
1996
- 1996-08-09 US US08/694,865 patent/US5837268A/en not_active Expired - Lifetime
-
1997
- 1997-08-08 DK DK97935395T patent/DK0920510T3/da active
- 1997-08-08 EP EP97935395A patent/EP0920510B1/en not_active Expired - Lifetime
- 1997-08-08 PT PT97935395T patent/PT920510E/pt unknown
- 1997-08-08 CA CA002262524A patent/CA2262524A1/en not_active Abandoned
- 1997-08-08 HU HU0001538A patent/HUP0001538A3/hu unknown
- 1997-08-08 PL PL97331537A patent/PL331537A1/xx unknown
- 1997-08-08 WO PCT/CA1997/000559 patent/WO1998006848A1/en active IP Right Grant
- 1997-08-08 TR TR1999/00267T patent/TR199900267T2/tr unknown
- 1997-08-08 ES ES97935395T patent/ES2247637T3/es not_active Expired - Lifetime
- 1997-08-08 BR BR9711123-6A patent/BR9711123A/pt not_active Application Discontinuation
- 1997-08-08 KR KR1019997001097A patent/KR20000029911A/ko not_active Application Discontinuation
- 1997-08-08 CN CNB971971617A patent/CN1328381C/zh not_active Expired - Fee Related
- 1997-08-08 AU AU38437/97A patent/AU725233B2/en not_active Ceased
- 1997-08-08 JP JP10509192A patent/JP2001502887A/ja not_active Ceased
- 1997-08-08 IL IL12812397A patent/IL128123A0/xx unknown
- 1997-08-08 AT AT97935395T patent/ATE300616T1/de not_active IP Right Cessation
- 1997-08-08 NZ NZ333999A patent/NZ333999A/xx unknown
- 1997-08-08 DE DE69733823T patent/DE69733823T2/de not_active Expired - Fee Related
-
1998
- 1998-07-29 US US09/124,491 patent/US6022960A/en not_active Expired - Fee Related
-
1999
- 1999-02-04 NO NO990533A patent/NO990533L/no not_active Application Discontinuation
- 1999-08-26 US US09/383,912 patent/US6521746B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1328381C (zh) | 2007-07-25 |
DK0920510T3 (da) | 2005-11-28 |
DE69733823T2 (de) | 2006-06-08 |
CA2262524A1 (en) | 1998-02-19 |
HUP0001538A2 (hu) | 2000-08-28 |
NO990533D0 (no) | 1999-02-04 |
EP0920510A1 (en) | 1999-06-09 |
HUP0001538A3 (en) | 2002-01-28 |
US5837268A (en) | 1998-11-17 |
AU3843797A (en) | 1998-03-06 |
BR9711123A (pt) | 2000-01-11 |
US6521746B1 (en) | 2003-02-18 |
KR20000029911A (ko) | 2000-05-25 |
NZ333999A (en) | 2000-07-28 |
PL331537A1 (en) | 1999-07-19 |
AU725233B2 (en) | 2000-10-12 |
IL128123A0 (en) | 1999-11-30 |
ES2247637T3 (es) | 2006-03-01 |
JP2001502887A (ja) | 2001-03-06 |
WO1998006848A1 (en) | 1998-02-19 |
PT920510E (pt) | 2005-11-30 |
US6022960A (en) | 2000-02-08 |
ATE300616T1 (de) | 2005-08-15 |
EP0920510B1 (en) | 2005-07-27 |
DE69733823D1 (de) | 2005-09-01 |
CN1233288A (zh) | 1999-10-27 |
NO990533L (no) | 1999-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR199900267T2 (tr) | GnRH-Lökotoksin kimeralari. | |
MX9706009A (es) | Quimeras de gnrh-leucotoxina. | |
DE69910580D1 (de) | Von der telomerase abgeleitete antigene peptide | |
NZ335485A (en) | Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof | |
MXPA04003333A (es) | Remodelado y glicoconjugacion de peptidos. | |
DE60109443D1 (de) | Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält | |
ES2187946T3 (es) | Uso de interleucina-15. | |
IT8419343A0 (it) | Antigene di peptide protettivo. | |
DE60042816D1 (de) | T-helferzellen-epitope | |
ES2152313T3 (es) | Gen grb-3-3, sus variantes y sus utilizaciones. | |
ATE314474T1 (de) | Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen. | |
DE69938130D1 (de) | Neue peptide | |
DE69619808D1 (de) | Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän | |
ATE356140T1 (de) | Gd3 mimetische peptide | |
DE69526087D1 (de) | Or-1, ein wais-rezeptor der nuklearen rezeptoren familie | |
DE69836485D1 (de) | Hepatitis e-virus aus dem schwein und dessen verwendungen | |
ES2193014T3 (es) | 3-metiloct-6-enoles 6-sustituidos. | |
EP0179412A3 (en) | Antigenic peptide compounds | |
TR200003608T2 (tr) | Moraxella Catarrhalis'e ait BASB027 proteinleri ve genleri. | |
DE69733026D1 (de) | Cyclin e spezifische konstrukte und komplexe |